IL305349A - New virus particles for medical purposes - Google Patents
New virus particles for medical purposesInfo
- Publication number
- IL305349A IL305349A IL305349A IL30534923A IL305349A IL 305349 A IL305349 A IL 305349A IL 305349 A IL305349 A IL 305349A IL 30534923 A IL30534923 A IL 30534923A IL 305349 A IL305349 A IL 305349A
- Authority
- IL
- Israel
- Prior art keywords
- virus particle
- segment
- lcmv
- seq
- carcinoma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10061—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21159746 | 2021-02-26 | ||
| PCT/EP2022/054766 WO2022180203A1 (en) | 2021-02-26 | 2022-02-25 | New virus particles for therapeutic purposes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL305349A true IL305349A (en) | 2023-10-01 |
Family
ID=74844711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL305349A IL305349A (en) | 2021-02-26 | 2022-02-25 | New virus particles for medical purposes |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4297763A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024508823A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230153411A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117241812A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022226407A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3208055A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2023002508A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL305349A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023009650A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022180203A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL326615A (en) | 2023-08-31 | 2026-04-01 | Abalos Therapeutics Gmbh | Virus particles with improved entry into tumor cells |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102015207036A1 (de) | 2015-04-17 | 2016-10-20 | Karl Sebastian Lang | Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften |
| EP3373959B1 (en) * | 2015-11-12 | 2022-06-29 | Hookipa Biotech GmbH | Arenavirus particles as cancer vaccines |
| DE102018215551A1 (de) * | 2018-09-12 | 2020-03-12 | Virolutions Biotech Gmbh | Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten |
-
2022
- 2022-02-25 WO PCT/EP2022/054766 patent/WO2022180203A1/en not_active Ceased
- 2022-02-25 KR KR1020237032657A patent/KR20230153411A/ko active Pending
- 2022-02-25 CN CN202280030958.8A patent/CN117241812A/zh active Pending
- 2022-02-25 JP JP2023551984A patent/JP2024508823A/ja active Pending
- 2022-02-25 CA CA3208055A patent/CA3208055A1/en active Pending
- 2022-02-25 EP EP22711182.0A patent/EP4297763A1/en active Pending
- 2022-02-25 IL IL305349A patent/IL305349A/en unknown
- 2022-02-25 AU AU2022226407A patent/AU2022226407A1/en active Pending
- 2022-02-25 MX MX2023009650A patent/MX2023009650A/es unknown
-
2023
- 2023-08-24 CL CL2023002508A patent/CL2023002508A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022226407A1 (en) | 2023-09-28 |
| EP4297763A1 (en) | 2024-01-03 |
| CA3208055A1 (en) | 2022-09-01 |
| WO2022180203A1 (en) | 2022-09-01 |
| AU2022226407A9 (en) | 2024-01-25 |
| JP2024508823A (ja) | 2024-02-28 |
| US20220273741A1 (en) | 2022-09-01 |
| CL2023002508A1 (es) | 2024-01-26 |
| KR20230153411A (ko) | 2023-11-06 |
| CN117241812A (zh) | 2023-12-15 |
| MX2023009650A (es) | 2023-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yin et al. | Dendritic-cell-targeting virus-like particles as potent mRNA vaccine carriers | |
| JP6740340B2 (ja) | 免疫優性アデノウイルスエピトープに突然変異を有する腫瘍溶解性アデノウイルスおよび癌処置におけるそれらの使用 | |
| KR102437072B1 (ko) | 암 백신 개발용 변형된 아데노바이러스 | |
| JP5797638B2 (ja) | ニューロンの発生、再生および保護 | |
| EP3003343A1 (en) | A biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases | |
| IL281299B1 (en) | Method for creating an arena virus directed against a tumor and for creating mutants of the virus | |
| Stachura et al. | Arenaviruses: Old viruses present new solutions for cancer therapy | |
| IL303121A (en) | Oncolytic herpes simplex viruses type 1 for the treatment of brain tumors | |
| IL296982A (en) | Peptide having mesenchymal stem cell mobilizing activity | |
| WO2022180203A1 (en) | New virus particles for therapeutic purposes | |
| AU2018316256B2 (en) | Oncolytic virus carrying E-cadherin and uses thereof | |
| IL296912A (en) | Immune-modulating preparations and their use | |
| US11384338B2 (en) | Oncolytic T7 bacteriophage having cytokine gene and displaying homing peptide on capsid and its use for treating melanoma | |
| WO2008013276A1 (en) | Therapeutic agent for malignant mesothelioma | |
| JP5036057B2 (ja) | リンパ管新生促進剤 | |
| CA3245759A1 (en) | NEW USE OF GENETICALLY MODIFIED MEASLES ONCOLYTIC VIRUS | |
| WO2025244125A1 (ja) | 新規ポリペプチド | |
| Unzueta Elorza | De novo design of self-assembling protein nanoparticles towards the gene therapy of colorectal cancer | |
| JPWO2020075836A1 (ja) | B型肝炎ウイルス複製阻害剤及びそれを含むb型肝炎治療用医薬組成物 | |
| Guinn et al. | International Society for Cell and Gene Therapy of Cancer: 2005 meeting in Shenzhen, China | |
| WO2025119999A1 (en) | Extracellular vesicle based vaccine platform |